Skip to main content
GeneralHomeInvestorsNews

Phase 1 data of mdc-TJK investigational long-acting injectable of olanzapine for schizophrenia patients, exhibited favorable characteristics of an extended-release profile

By May 22, 2023March 15th, 2024No Comments1 min read